Skip to main content
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. — Investor Relations & Filings

Ticker · PMN ISIN · CA74346M1095 LEI · 5299007HZF79F9IAXI53 US Professional, scientific and technical activities
Open in API
Filings indexed 333 across all filing types
Latest filing 2022-11-01 Capital/Financing Update
Country CA Canada
Listing US PMN

About ProMIS Neurosciences Inc.

https://www.promisneurosciences.com/

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.

Recent filings

Filing Released Lang Actions
FORM S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC by ProMIS Neurosciences Inc. It is a preliminary prospectus related to the registration of common shares and warrants for public offering. The text includes detailed information about the offering, risk factors, business description, management discussion and analysis, executive compensation, and other disclosures typical of a registration statement for securities issuance. This type of filing is related to capital raising and securities registration rather than a financial report, earnings release, or management discussion alone. Therefore, the document fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2022-11-01 English
SC 13G
Major Shareholding Notification
2022-10-21 English
Regulatory Filings 2022
Regulatory Filings
2022-10-21 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 11, 2022, by ProMIS Neurosciences Inc. It details the entry into material definitive agreements related to a private investment in public equity (PIPE) financing, including Unit Purchase Agreements, Registration Rights Agreements, and Placement Agent Agreements. The document describes the terms of the financing, the securities involved, and related fees. It also includes references to exhibits such as agreements and a press release. The content focuses on a capital raising event and related agreements, which fits the definition of a Capital/Financing Update. The document is not an annual or quarterly report, audit report, or earnings release, nor is it a proxy, voting result, or management change announcement. It is a current report on a material financing transaction, thus best classified as Capital/Financing Update (CAP). The document length (8745 characters) and detailed content support this classification with high confidence.
2022-10-17 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-09-20 English
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-09-20 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.